No public results for “Take the Biopharma Sentiment Index” Q1 2026 yet
No publicly indexed survey or news item specifically titled “Take the Biopharma Sentiment Index” for Q1 2026 appears in current search results; the exact branded index or quarter you asked for does not show up in accessible news or survey reports.1
Recent life sciences and biopharma survey coverage instead describes a broader 2026 outlook in which biopharma executives are described as cautiously optimistic about 2026, with improving deal flow and growth expectations.1
In that 2026-oriented survey, 45% of biopharma leaders and 51% of medtech leaders cite mergers and acquisitions as a top near‑term strategic priority, indicating strengthening sentiment toward external growth.1
43% of biopharma executives say their R&D priorities include expanding portfolios into new therapeutic areas and modalities, expecting large molecules, cell, gene and RNA therapies, and ADCs to drive revenue over the next 2–3 years.1
The same survey reports growing focus on AI-enabled platforms, with 39% of biopharma respondents seeing AI investments as a key growth driver for 2026, reinforcing a sentiment shift from AI as a productivity tool to a growth catalyst.1
Perceived risks in 2026 have shifted versus the prior year’s survey:
geopolitical and economic uncertainty rose to a concern for 39% of respondents (from 19% previously), and 38% cite inflation, broader economic pressures, and supply chain risks as key strategy shapers.1
Regional sentiment is uneven:
about 90% of biopharma leaders in Europe and Asia are positive or cautiously positive on 2026, compared with 56% in the US, where 27% are negative or uncertain about the outlook.1
Given the lack of any clearly identified “Biopharma Sentiment Index” Q1 2026 publication, the most closely related and recent information about biopharma sentiment toward 2026 comes from these broader life‑sciences executive surveys rather than from a named index product.1
Sources:
1. https://www.soci.org/news/2025/12/life-sciences-why-execs-are-cautiously-optimistic-about-2026